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tion of all direct costs we determined that the total average cost of uncomplicated 
hypothyroidism during pregnancy and childbed per women was € 124.79. In the 
cost structure of health care provision for pregnant women with uncomplicated 
hypothyroidism the most significant costs are spent on thyroid laboratory tests.
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Objectives: Diabetes is a major economic burden disease globally. The geriatric 
diabetic cost economic studies in India are limited. Hence this study carried out 
with the objective to assess the various costs incurred during the geriatric dia-
betic treatment (COI model). MethOds: This was a prospective, cross sectional 
study conducted from July 2012-July 2014 in the General Medicine Department of 
Kasturba Medical College Hospital, Manipal, after obtaining ethical clearance. Cost 
details were obtained from hospital finance and pharmacy. The Descriptive sta-
tistical method was applied Results: A total of 475 cases were enrolled of which 
52.42% had diabetes. Of this, 27.71% had DM alone, 6.82 % had DM associated renal 
disease (i.e.: 3.6% were DMAKI, 3.2% were DMCKD), 12.44% had other than renal 
DM complications (microvascular), 48.19% had both DMHTN, 4.81% had DMHTN 
associated complications. The total cost incurred for the treatment of the disease 
and its related complications (DM alone, DMAKD, DMCKD, DM neurological compli-
cations, DMHTN & DMHTN) did not vary significantly [ I.e. Mean+ SD (INR): 16044.7 
+ 37740.06, 15374.51+ 11915.94, 14840.03+14124.05, 8395.35+ 16580.11, 27130.28 + 
64934.04, 14430.5+ 13113.78 ) . The cost of treatment (INR) appeared low due to vary-
ing factors like free screening or treatment for other symptoms, etc. The cost based 
on various factors were as listed - Medicine charge > Laboratory/diagnostic charges 
> Nursing charges > Material charges > Procedure charges > Professional charges 
> Admission related charges > Miscellaneous charges. cOnclusiOns: This study 
clearly suggests that medicine expense is the highest cost factor in DM treatment. 
The second highest cost was laboratory followed by nursing costs. Research on 
pharmacoeconomic models like cost effective analysis (CEA), Cost minimization 
analysis (CMA), and Cost benefit analysis (CBA) by the pharmacist &the stakehold-
ers is essential to reduce the burden in geriatrics. Lack of availability of direct non-
medical cost was the limitation of this study
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Objectives: as a result of type II Diabetes Mellitus (T2DM), patient may develop sev-
eral complications, which cause serious economic burden to health care system. The 
objective of the study was to evaluate the treatment cost of T2DM in Estonia for 4 
serious complications: myocardial infarction (MI), stroke, nephropathy and retinopa-
thy during the year, when the event developed and a year later. MethOds: anony-
mous data about T2DM patients´ treatment records was obtained from Estonian 
Health Insurance Fund for the years 2001-2011. The complications were defined 
by ICD-10 codes and following criteria were applied for the sample to be analysed: 
the complication had been detected first time between the years 2004-2008 (no 
complication during the preceding 3 years). The data did not include outpatient 
medication consumption. The control group consisted of randomly chosen T2DM 
patients, who did not have the complication during this time period. Data analy-
sis was performed using Stata 11. Results: the overall sample consisted of 3016 
patients (age 45-69). Inpatient and outpatient treatment costs were calculated for 
MI, stroke, nephropathy and retinopathy for the year, when the event occurred, and 
for the year later. The highest treatment costs appeared during the year, when the 
event was recorded, and were for the MI 6,844, stroke 4,113, nephropathy 3,473 and 
retinopathy 598 EUR. A year later the costs were 1,860 (-73%), 2824 (-32%), 2490 (-29%) 
and 701 (+17) accordingly. cOnclusiOns: MI and stroke are amongst highest costs 
during the first year and a year later the costs are lower, however for retinopathy 
the cost is higher than the first year. A year later, cost of stroke remains higher than 
MI, presumably due to follow-up care. The complication cost data obtained gives 
information about the healthcare expenditure in Estonia and can be used for cost-
effectiveness assessment for new diabetes medications.
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Objectives: The number of patients in the Czech Republic treated for diabetes in 
2013 was nearly 862 thousand. The Type 2 diabetes mellitus share was 91.7 %. The 
number of treated diabetics has been increasing in a long-term trend as well as 
the number of their chronic complications. The goal of the study is to estimate the 
cost of type 2 diabetes from the health insurance perspective in a newly established 
regional diabetology outpatient facility. MethOds: The cost-of-illness analysis of 
the direct costs was performed from the third-party payer perspective based on 
data from the year 2014. The bottom-up approach was used. Data of all 552 patients 
with Type 2 diabetes were (all patients with Type 2 Diabetes in the ambulance) 
were taken into consideration. Altogether 1 696 consultations were provided to the 
patients during the particular year. Results: The average cost of consultations for 
one type-2-diabetes patient per year was CZK 840.56 (~EUR 30.5), the average cost 
of treatment for one patient was CZK 10 336 (~EUR 375), the average material cost 
was CZK 2 835 (~EUR 103) per patient, and CZK 113.7 (~EUR 4) was the average cost 
for amputation per patient, and the average cost of diabetic nephropathy was CZK 
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Objectives: The aim of this study was to assess the indirect costs associated 
with types 1 diabetes mellitus (DM) from the perspective of the Social Insurance 
Institution (ZUS) in Poland. MethOds: The estimates were based on data from 
the year 2013 concerning absence from work due to the illness (sick leave) the 
amount of short-term disability, the sufferers of which claim rehabilitation ben-
efit, and the amount of permanent (or long-term) disability, the sufferers of which 
claim disability pension. Cost analysis was performed based on the Human Capital 
Approach taking into account Gross Domestic Product (GDP) per capita equaled 10 
278 EUR. Results: Total indirect costs of DM types 1 in the year 2013 in Poland 
were 80 148 008 EUR. Total indirect costs associated with absenteeism were 8 263 
EUR calculated using GDP per capita per patient. The highest component of indirect 
costs of DM type 1 was long-term disability, in particular unlimited period, which 
accounted for 71%. Long-term (limited period), short term disability and sick leave 
costs constitute 17%, 3% and 9% of total indirect costs of DM type 1, respectively. 
One sick leave of a person with types 1 diabetes generated a cost of lost productiv-
ity equal to 431 EUR. The cost of disability pension per one person was higher than 
rehabilitation benefit, and equalled 20 600 EUR (limited period) and 362 505 EUR 
(unlimited period) compared with 3 611 EUR. cOnclusiOns: DM in Poland gener-
ated high indirect costs. The main component was long-term disability, in particular 
unlimited period; rehabilitation benefit and disability pension (limited period) and 
sick leave generated much lower costs for Social Insurance Institution.
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Objectives: This is the first study that assesses the economic costs of Type 1 
Diabetes Mellitus (T1DM) in pediatric patients in Spain. The main objective of this 
study was to estimate direct healthcare costs (DHC) and direct non-healthcare costs 
(DNHC) of T1DM in children and adolescents. MethOds: CHRYSTAL (Costs and 
Health Related qualitY of life Study for Type 1 diAbetes meLlitus pediatric patients 
in Spain) is an observational study conducted in 2014 on a representative sample of 
275 patients aged 1-17 years diagnosed with T1DM, distributed across 12 hospitals 
in Spain. The study followed a bottom-up-approach to costing from a societal per-
spective. Data on demographic and clinical characteristics, health resource utiliza-
tion, and informal care were collected cross-sectionally from medical records and 
questionnaires completed by clinicians and patients´ caregivers. The reference year 
for unit prices was 2014. Results: The average annual cost for a T1DM patient was 
€ 27,349. DHC amounted to € 4,144, with statistically significant differences depend-
ing on glycemic control (HbA1c < 7.5% versus HbA1c ≥ 7.5%): € 3,683 versus € 4,788 
(p< 0.05) and the existence of patient with acute and chronic complications (except 
hypoglycemia) and related comorbidities (with versus without): € 5,777 versus € 3,713 
(p< 0.05) after controlling for age and gender. The largest DHC were diabetes supplies 
(€ 2,035), outpatient visits (€ 841), and medication (€ 670). Average DNHC were € 23,204. 
Informal care (the time that caregivers spend in T1DM related caregiving tasks) 
represented 97.5% of DNHC (€ 22,618) and 82.7% of total costs. cOnclusiOns: T1DM 
in children and adolescent patients carries a considerable social economic burden, 
especially in terms of informal care, which accounts for the largest proportion of 
total costs associated to the disease. The results shed light on the allocation of 
T1DM related resources, and might enlighten T1DM policy priority setting in Spain.
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bAckgROund: Hypothyroidism is a common disease during pregnancy with 
important medical and social significance. However, there is no real study eval-
uating the economic analysis of this pathology during pregnancy and childbed 
in Czech Republic. Objectives: To determine the real medical cost associated 
with uncomplicated hypothyroidism during pregnancy and childbed in Czech 
Republic. MethOds: The 10 years retrospective non-randomized cross-sectional 
study was performed in 172 pregnant women with hypothyroidism with uncom-
plicated disease course who were followed and examined according to the rec-
ommendation of the guidelines of American Thyroid Association. The study was 
performed in the settings of Departments of Endocrinology of a university hospital 
and with laboratory assessment in a single center. We assessed serum concentra-
tions of thyroid hormones and finally, we calculated the cost of illness to estimate 
the cost of health care for uncomplicated hypothyroidism during pregnancy and 
childbed. Results: Of the 172 positively screened women in the first trimester, 112 
(65.12%) had subclinical hypothyroidism and 40 (34.88%) had overt hypothyroidism. 
Seventy (40.7%) had already been treated for hypothyroidism before inclusion in 
the study and 102 (59.3%) were newly diagnosed. The median dose of levothyroxine 
was 58.83ug/day (range: 0-174) and median frequency of laboratory and medical 
check-up was 4.5 (range 3-6). The total average annual cost of laboratory tests was 
€ 852.91, the cost of entrance endocrine examination € 229.02, follow-up endocrine 
examination € 364.92 and levothyroxine therapy € 105.65. The total average cost of 
first medical and laboratory check-up during pregnancy per women was € 34.67 and 
of one follow-up examination € 17.67 per women. cOnclusiOns: After calcula-
